The medical recommendations for adult LCH have been published in Orphanet Journal of Rare Diseases.

More ...
An­nu­al in­ter­na­tio­nal con­fe­rence of sci­en­tists, pa­tho­lo­gists and cli­ni­ci­ans discussing histiocytoses and their backgrounds. More ...
An International Community of Professionals Dedicated to Research and Treatment More ...
PubMed comprises more than 20 million citations for biomedical literature from MEDLINE, life science journals, and online books. More ...

European Union Clinical Trials Register of the European Medicines Agency

More ...

European Clinical Trials Database of the European Medicines Agency

More ...
Rare diseases in EU
Why do rare diseases need specific EU support? More ...
Euro Histio Net has received funding from the European Union, in the framework of the Public Health Programme. More ...


Author(s): Euro Histio Net Work Group for LCH Guidelines for adults (see introduction page), Created: 2012/07/26, last update: 2013/08/18


In contrast to treatment of childhood LCH, radiotherapy is still a feasible and effective treatment option for adult patients with LCH. It has a long tradition and the first successful radiation of LCH was described in 1930 by Sosman. Since then, the effectiveness of radiotherapy in LCH has been shown in a large number of publications, but all studies reported in literature have a retrospective nature and in general the number of patients is not large. [Atalar et al 2010; Gaundong Mbéthé et al 2010; Brady et al 2008; Greenberger et al 1979; Heyd et al 2000].


Radiotherapy indications should respect the age of patients, the possibility of radiogenic malignancies, and the semi-benign character of disease. This kind of treatment should be considered as a palliative measure only when it is clearly warranted by the presence of disease progression or when location and extent of disease threaten the function of critical organs.

Table 6: Possible indications for the use of radiotherapy in adults



Grade *

Isolated “unresectable” lesion:

  • if a resection would significantly compromise anatomic function, e.g. odontoid peg, CNS


Recurrent or progressive lesion:

  • In multifocal or multisystem disease only in case of minor response to standard systemic therapy.


Adjuvant treatment following marginal or incomplete resection:

  • especially in single system bone disease with soft tissue involvement


* Grades of recommendation see here.


Most literature data concerning radiotherapy in adult LCH deal with uni- or multifocal osseous single-system disease. Summarizing the results in these bone lesions, the local control rates ranged from 75-100%, complete remission from 79-100%, respectively. There is not much data in the literature on radiotherapy in non-osseous single-system disease, mostly presented as single case reports. Nevertheless, in most cases a complete remission is reported. Bony lesions are the predominantly irradiated manifestations also in multi-system disease. Local control rates ranged from 75% to 100%, complete remission rates were up to 85%. Thus in case of minor responsiveness to standard systemic therapy Radiotherapy may be considered as an additive treatment in multifocal or multisystem disease.

Radiotherapy technique and dose

Osseous and visceral lesions should be treated with megavolte equipment (Linear accelerator), whereas superficial x-rays or fast electrons are used for cutaneous or subcutaneous lesions. In external beam radiotherapy, individually optimized radiation set-up and shielding using a modern three-dimensional conformal radiotherapy technique should be used to minimize the volume of not affected tissue neighboring the disease lesion. An adequate margin of 1-2 cm of normal tissue around the treated lesion should be included, but in bony lesions the whole bone must not to be included [Micke/Seegenschmiedt 2002].

The dose recommendation for radiotherapy is still controversial, because the optimal dose is not well defined, and an exact dose-effect relationship has not been established. There is a wide dose range of applied total doses from 1,4 Gy up to 45 Gy. In general, a dose range from 10 to 20 Gy is recommended in adults but a dose range from 12-14 Gy should sufficient for local control. Such total doses should be delivered in fractions of 1-2 Gy per day to avoid a possibly limited capacity for tissue repair mechanisms in larger single doses [Brady et al 2008; Cassady 1987]). (Grade C2 *)

Side effects

Acute side effects of radiotherapy depend on the localization of the irradiated body site. As the applied total dose rarely exceeds 20 Gy, both acute and subacute side effects are rare. Most literature data do not provide any information about acute side effects of radiotherapy. Late side effects of radiotherapy are also rare due to the low applied dose range. The only risk, which should be mentioned, is the extremely low one of radiation-induced carcinogenesis. [Greenberger et al 1979] reported a rate of 3.9% for induction of malignant tumors, but this data should be interpreted with care, because many children were treated in this collective. Even though the doses applied for local control in adult LCH are low, several publications in the literature describe the induction of leukemia, osteosarcoma, teratoma, malignant meningioma, thyroid and liver tumors (but it must be considered that most studies also treated children, who bear a much larger risk of cancer induction, and there is a well-known tendency of patients with LCH to develop malignancies independently of therapies.


Finally, the radiation treatment technique has substantially improved during the last decade becoming a precise and normal tissue sparing instrument. Nevertheless, the indication for radiotherapy for a palliative treatment in LCH has to be accurately set up with and the potential benefits of radiation treatment must be carefully weighed against its possible risks. The exact target cells or structures affected by radiotherapy in LCH remain unclear. Low doses of radiotherapy not reaching a normal cell-killing level have been shown to heal the disease, resulting in theories, that either radiotherapy suppresses an inflammatory process and so reduces the de novo- fraction of Langerhans cells, or that Langerhans cells themselves are a very sensitive population to irradiation [Greenberger et al 1979].

Recommended indications for the use of radiotherapy in adults with LCH are listened in table 6.

* Grades of recommendation see here.


[Atalar et al 2010] Atalar B, Miller RC, Dincbas FO, Geismar JH, Micke O, Akyurek S, Ozyar E: Adult langerhans cell histiocytosis of bones : a rare cancer network study. Acta orthopaedica Belgica 2010, 76: 663 [PMID: 21138223]

[Gaundong Mbéthé et al 2010] Gaundong Mbéthé GL, Dejean C, Henriques de Figueiredo B, Sargos P, Italiano A, Kantor G: [Multifocal Langerhans cell histiocytosis of bone: indications for radiotherapy]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 2010, 14: 759 [PMID: 20674449]

[Brady et al 2008] Brady, LW, Heilmann, HP, Molls M, Nieder, C (eds): Radiotherapy for Non-Malignant Disorders. Chapter: Langerhans Cell Histiocytosis, ed. Olschewski,T, Seegenschmiedt,MH, Micke,O Springer Verlag 2008, 397 [ISBN: 978-3-540-62550-6

[Greenberger et al 1979] Greenberger JS, Cassady JR, Jaffe N, Vawter G, Crocker AC: Radiation therapy in patients with histiocytosis: management of diabetes insipidus and bone lesions. International journal of radiation oncology, biology, physics 1979, 5: 1749 [PMID: 316811]

[Heyd et al 2000] Heyd R, Strassmann G, Donnerstag F, Martin T, Zamboglou N: [Radiotherapy in Langerhans-cell histiocytosis. 2 case reports and review of the literature]. Rontgenpraxis; Zeitschrift fur radiologische Technik 2000, 53: 51 [PMID: 10994366]

[Micke/Seegenschmiedt 2002] Micke O, Seegenschmiedt MH, German Working Group on Radiotherapy in Germany: Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. International journal of radiation oncology, biology, physics 2002 Feb 1; 52: 496 [PMID: 11872298]

[Cassady 1987] Cassady JR: Current role of radiation therapy in the management of histiocytosis-X. Hematology/oncology clinics of North America 1987, 1: 123 [PMID: 3312144]